Navigation Links
NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
Date:9/1/2009

aw with our VLP vaccine candidate as compared with the egg-based vaccine, we are now particularly excited to begin the larger head-to-head study in elderly adults this Fall," Dr. Heaton said.

The results of this study are strongly supportive of accelerated development of Novavax's pandemic influenza vaccines, including the novel H1N1 2009 influenza VLP vaccine. "We are working tirelessly with partners and governments worldwide to potentially provide H1N1 vaccine to regions without an indigenous supply," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "The current influenza pandemic underscores the potential for Novavax's advanced influenza vaccine technology to have significant public health impact by providing vaccine in time to those in need," said Dr. Singhvi.

Seasonal and Pandemic Influenza

Seasonal epidemics of influenza cause an estimated 200,000 hospitalizations and 36,000 deaths in the US each year. With the H1N1 2009 influenza pandemic, US health officials are projecting an additional 30,000 to 90,000 deaths will occur during the upcoming influenza season and approximately 40% of US citizens will be infected. Because the H1N1 2009 virus is a new strain, individuals lack antibody to fight it. Good handwashing, coughing into a sleeve, and staying home when ill are some ways to prevent H1N1 flu; however, the most effective way to prevent it is through vaccination.

Globally, seasonal flu infects between 5 percent and 20 percent of the population and kills between 250,000 and 500,000 people each year. Because of the limited number of individuals with antibody against the novel H1N1 2009 virus, the World Health Organization (WHO) has projected that up to a third of the world's population may be infected this year, with as many as 15% of those requiring hospital care.

About Novavax

Novavax is a clinical-stage biotechnology
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
2. Novavax Reports Second Quarter 2009 Financial Results
3. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
4. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
6. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
7. Novavax Announces Repayment of $5 Million of Convertible Debt
8. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
9. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
10. Novavax Appoints Stanley Erck to Board of Directors
11. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... , , , ... when revenues aren,t growing, many organizations are looking for ways to ... these things by better managing processes and the documents that go ... applications ( http://onbase.com/English/Products ). But here,s the roadblock: budgets ...
... , THE WOODLANDS, Texas, Sept. 9 Lexicon ... focused on discovering and developing breakthrough treatments for human disease, announced today ... and chief executive officer, will present at the Morgan Stanley Global Healthcare ... on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time. ...
... England, September 9 Clinical Therapeutics,(, http://www.clinicaltherapeutics.com/ ) ... the addition of Michael G. Spigarelli, MD, PhD,to ... As section editor for the Pediatric, Adolescent, ... Research section), Dr. Spigarelli brings a wealth of ...
Cached Biology Technology:Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 2Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 3Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 4Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section 2
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... 8, 2014 Fingerprint Cards, ... design win (DW). An Asian OEM has selected FPC1021 for ... start in August 2014.   FPC is proud ... has a planned date for start of mass production in ... of SEK 5M, for delivery in the first half of ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... an effective vaccine for hepatitis B and public health officials ... for the infectious liver disease, tens of thousands of people ... to a new study by researchers at Brown University, missed ... why infections persist. "This is a really simple thing ...
... - A comprehensive multi-disciplinary synthesis just published in ... investigation and policy development to address significant environmental, social ... climate change. "Effects of climate change on the ... synthesis of range change prediction in a warming world" ...
... Mass. Geoscientists at the University of Massachusetts Amherst ... first evidence that warm-cold climate oscillations well known in ... also appear as tropical rainfall variations in the Amazon ... expression of these cycles in the Southern Hemisphere. ...
Cached Biology News:Many high-risk Americans don't get hepatitis B vaccine 2Many high-risk Americans don't get hepatitis B vaccine 3Climate change invites alien invaders - Is Canada ready? 2Evidence of past Southern hemisphere rainfall cycles related to Antarctic temperatures 2
... be superior to transfection in some applications. ... PULSin you can study lethal proteins and ... proteins in cells. Likewise, delivery of blocking ... RNA interference experiments. ,With PULSin you ...
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
... The versatile ST-195 allows real-time observations of ... This instrument has 64 different strain parameters ... incubator. The thin silicon strain chamber used ... microscopes and fluorescence microscopy. ST-195 can be ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
Biology Products: